Skip to main content
. Author manuscript; available in PMC: 2011 Nov 27.
Published in final edited form as: Pain. 2007 Apr 20;132(1-2):108–123. doi: 10.1016/j.pain.2007.03.003

Figure 9.

Figure 9

Changes in the expression of NMDA NR2B with peripheral neuropathy and after treatment with D-cycloserine (DCS). Expression levels of NR2B were lower in the mPFC of SNI animals, in comparison with sham animals (n = 5–7 animals per group; arbitrary units normalized to GADPH). Moreover, treating SNI animals with DCS orally for 2 wks (30 mg/kg) reversed this pattern. Expression levels for NR2A, NR1, and gluR1 in mPFC were not affected by SNI injury or DCS treatment. Asterisks indicate statistically significant differences. Error bars indicate S.E.M.